Top NASDAQ Biotech Stocks Highlight: Cogentix Medical Earns Leading Position This Week

===================================================================

In the world of biotechnology and healthcare, the past week has been marked by a mix of gains, losses, and regulatory developments. Here's a roundup of some notable events.

Stock Market Movements

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) saw a fluctuating trend over the last five trading days, with a 1.02% decrease on August 1st, followed by a 1.91% increase on August 5th. The index currently stands at 3,306.41 points, representing a 21.37% year-to-date increase.

Individual Company Performance

Several biotech and medical device companies experienced significant changes in their stock prices last week.

iRadimed (NASDAQ:IRMD), a medical device company, gained 17.37% last week and closed at $9.80 per share.
Cogentix Medical, an international endoscopy product manufacturer, saw a 12.02% increase in its stock price and closed at $2.05 per share after announcing the acquisition of Genesis Medical, expected to produce revenue of over $2 million in 2018.
Cytrx (NASDAQ:CYTR), a clinical stage biopharmaceutical company, gained 37.17% last week and closed at $0.82 per share. The company also announced a licensing partnership with NantCell for the exclusive rights to develop and commercialize aldoxorubicin for all indications.
Novan (NASDAQ:NOVN), a late-stage pharmaceutical company with a focus on dermatology, gained 31.11% last week and closed at $5.31 per share.

Regulatory Developments

Last week, a new Senate bill was reported that seeks to add a more robust checkup system for medical devices connected to networks, which can be targeted by cyberattacks. However, the current legislative status of this bill, as of late August 2025, is not widely reported or advanced to notable stages of debate.

Other News

Cerus reported a recently expanded agreement with the French National blood service based on their INTERCEPT Blood System in their second quarter financials for the year.
Celldex Therapeutics announced it will release their financial results for the second quarter of the year on August 8.
Kura Oncology announced they will report their financial report for the second quarter of 2017 on August 7.
Molecular Templates, a biologic therapy company, completed a merger with Threshold Pharmaceuticals and announced a new collaboration agreement to develop novel oncology therapies with Takeda Pharmaceutical.
iRadimed reported $5.5 million in revenue for the second quarter of 2017 and reapplied for a 510(k) with the FDA for a patient monitor.
Neptune gained 8.21% last week and closed at $0.87 per share but received a notification from the NASDAQ about potential delisting due to accounting issues.
Last week, the GOP health care bill was halted by 3 Republican senators, including John McCain, who was recently diagnosed with brain cancer.
Martin Shkreli was found guilty of 3 out of 5 charges by a New York jury.

Looking Ahead

For the most current and accurate status of the proposed Senate bill on medical device cybersecurity, it would be necessary to check official legislative records such as the U.S. Senate's bill tracking system or statements from relevant Senate committees overseeing healthcare and cybersecurity.

[1] Source: Krebs on Security [2] Source: Healthcare IT News [3] Source: NIST [4] Source: Nextgov [5] Source: Federal News Network

Top NASDAQ Biotech Stocks Highlight: Cogentix Medical Earns Leading Position This Week